- Human pathology

Home > A. Molecular pathology > Targeted therapy > Therapeutical antibodies > ocrelizumab


Thursday 5 January 2017


Ocrelizumab is a humanized anti-CD20 monoclonal antibody. It targets CD20 marker on B lymphocytes, and hence is an immunosuppressive drug candidate.


It is under development as a treatment for multiple sclerosis by Hoffmann–La Roche’s subsidiary Genentech.

It reached Phase III clinical trials for rheumatoid arthritis and lupus erythematosus and Phase II for multiple sclerosis (MS) and hematological cancer.

In March 2010, Roche announced the suspension of clinical trials in rheumatoid arthritis and lupus erythematosus. This step followed excess deaths due to opportunistic infections. Development for multiple sclerosis continued.